Why VIVUS (VVUS) Stock Is Up Today

NEW YORK (TheStreet) -- Shares of VIVUS  (VVUS) rose 12.92% to $4.38 in morning trading Thursday after the FDA approved the company's erectile dysfunction drug Stendra.

The drug cuts in half the time necessary between taking the pill and engaging in sexual activity. Stendra is the first FDA-approved oral erectile dysfunction drug that one can take approximately 15 minutes before sexual activity. Viagra, Pfizer's  (PFE) famous blue pill, can be taken an hour prior to sex.

Vivus developed the drug with Auxilium Pharmaceuticals (AUXL) , which is currently mulling a takeover offer from Endo International (ENDP) .

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More than 11 million shares had changed hands as of 10:17 a.m., compared to the average volume of 1,462,930.

VVUS Chart VVUS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Global Stocks Retreat as U.S.-China Trade War Intensifies

Global Stocks Retreat as U.S.-China Trade War Intensifies

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods